Citadel Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Citadel Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.29M	Sell	10,000 -8,700	-47%	-$1.95M	﹤0.01%	5803
2025 Q4	$3.99M	Buy	18,700 +10,300	+123%	+$2.13M	﹤0.01%	4660
2025 Q3	$1.67M	Buy	8,400 +4,400	+110%	+$821K	﹤0.01%	6444
2025 Q2	$690K	Sell	4,000 -2,800	-41%	-$456K	﹤0.01%	7872
2025 Q1	$1.06M	Sell	6,800 -5,900	-46%	-$843K	﹤0.01%	6834
2024 Q4	$1.75M	Sell	12,700 -14,000	-52%	-$1.84M	﹤0.01%	5914
2024 Q3	$3.99M	Buy	26,700 +19,000	+247%	+$2.57M	﹤0.01%	4315
2024 Q2	$1.05M	Sell	7,700 -200	-3%	-$27.2K	﹤0.01%	6481
2024 Q1	$1.19M	Buy	7,900 +2,800	+55%	+$400K	﹤0.01%	6564
2023 Q4	$642K	Sell	5,100 -9,200	-64%	-$917K	﹤0.01%	7569
2023 Q3	$1.34M	Sell	14,300 -4,100	-22%	-$384K	﹤0.01%	5989
2023 Q2	$1.64M	Buy	18,400 +8,300	+82%	+$722K	﹤0.01%	5511
2023 Q1	$1.08M	Sell	10,100 -21,800	-68%	-$2.49M	﹤0.01%	6598
2022 Q4	$3.9M	Buy	31,900 +24,400	+325%	+$2.83M	﹤0.01%	4281
2022 Q3	$774K	Sell	7,500 -5,700	-43%	-$540K	﹤0.01%	7543
2022 Q2	$1.23M	Sell	13,200 -26,300	-67%	-$2.48M	﹤0.01%	6549
2022 Q1	$4.64M	Buy	39,500 +27,800	+238%	+$3.22M	﹤0.01%	4319
2021 Q4	$1.57M	Sell	11,700 -3,500	-23%	-$521K	﹤0.01%	6779
2021 Q3	$2.42M	Buy	15,200 +2,100	+16%	+$287K	﹤0.01%	5878
2021 Q2	$1.72M	Buy	13,100 +1,900	+17%	+$253K	﹤0.01%	6966
2021 Q1	$1.44M	Buy	11,200 +2,000	+22%	+$304K	﹤0.01%	7204
2020 Q4	$1.53M	Buy	9,200 +4,600	+100%	+$761K	﹤0.01%	5923
2020 Q3	$710K	Buy	4,600 +1,700	+59%	+$244K	﹤0.01%	6660
2020 Q2	$429K	Sell	2,900 -4,900	-63%	-$673K	﹤0.01%	7334
2020 Q1	$878K	Buy	7,800 +4,300	+123%	+$559K	﹤0.01%	5561
2019 Q4	$487K	Sell	3,500 -8,200	-70%	-$911K	﹤0.01%	6837
2019 Q3	$1.13M	Buy	11,700 +3,200	+38%	+$357K	﹤0.01%	5391
2019 Q2	$979K	Sell	8,500 -102,800	-92%	-$12.3M	﹤0.01%	5731
2019 Q1	$13.1M	Buy	+111,300	New	+$9.75M	0.01%	1753
2018 Q4	–	Sell	-6,700	Closed	-$475K	–	9066
2018 Q3	$475K	Buy	+6,700	New	+$461K	﹤0.01%	6779

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors's ASND Position: Q1 2026 in Review

Citadel Advisors sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 519,516 shares — an estimated $116M sold.

Citadel Advisors first reported a position in ASND in Q1 2015 and held it in 34 quarters. The position peaked at $175M in Q1 2025. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Citadel Advisors reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 519,516 Ascendis Pharma A/S shares in Q1 2026, an estimated $116M.
Citadel Advisors first reported a position in Ascendis Pharma A/S in Q1 2015 and held it in 34 quarters.
Citadel Advisors's Ascendis Pharma A/S position peaked at $175M in Q1 2025.
273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.